ELISA assay employing epitope-specific monoclonal antibodies to quantify circulating HER2 with potential application in monitoring cancer patients undergoing therapy with trastuzumab by Agnolon, V. et al.
1Scientific RepoRtS |         (2020) 10:3016  | https://doi.org/10.1038/s41598-020-59630-y
www.nature.com/scientificreports
eLiSA assay employing epitope-
specific monoclonal antibodies 
to quantify circulating HER2 with 
potential application in monitoring 
cancer patients undergoing therapy 
with trastuzumab
Valentina Agnolon  1,4,6, Anna contato  1,6, Anna Meneghello  2,5,6, Elda tagliabue  3, 
Giuseppe toffoli  2, Massimo Gion  1, Federico polo  2,5* & Aline S. c. fabricio  1*
Circulating HER2 extracellular domain (HER2 ECD) levels were proposed as a surrogate for HER2 
tissue expression to monitor breast cancer patients for early relapse or responses to standard or 
HER2-targeted therapies, such as the monoclonal antibody (mAb) trastuzumab. Currently, available 
commercial ELISA assays for HER2 ECD rely on antibodies recognizing undisclosed or unknown 
epitopes. In this work, two ELISA assays employing MGR2 and MGR3 epitope-specific mAbs for HER2 
ECD were developed and validated, showing good assay precision and linearity of the dose-response 
signal within the dynamic range of 0.19–12.50 ng mL−1 and detection limits of 0.76 and 0.75 ng mL−1 
for the MGR2 and MGR3 assays, respectively. The developed assay showed a good agreement with two 
widely used commercial kits for HER2 ECD quantification in serum samples from breast cancer patients. 
A complete characterization of mAb-HER2 ECD interaction was performed by means of surface 
plasmon resonance using trastuzumab as control for both epitope mapping and kinetics analysis. The 
epitopes recognized by the two mAbs showed no overlap with trastuzumab, which was confirmed by 
trastuzumab interference analysis in serum samples. The method showed to be a practical approach to 
determine HER2 ECD with a high degree of sensitivity, reliability and recovery in samples containing 
mAbs-based therapies.
HER2 is a trans-membrane tyrosine kinase receptor, member of the epidermal growth factor receptor (EGFR) 
family. Abnormal expression of HER2 was observed in a number of primary tumors, including breast cancer 
(BC) and gastric cancer, where HER2 gene is overexpressed in approximately 30% and 24% of patients, respec-
tively1,2. Determination of HER2 overexpression in BC tissue has a role in clinical decisions, as it is associated 
with an unfavourable prognosis, especially in patients with lymph node metastases3, with greater resistance to 
hormonal therapy and some chemotherapeutical agents4,5 and with increased sensitivity to other chemotherapy 
regimens6,7. Moreover, HER2 protein tissue expression has been employed as an important predictive factor to 
take decision about anti-HER2 therapeutic approaches such as the use of monoclonal antibodies (mAbs) tras-
tuzumab (Herceptin™, Genentech) and pertuzumab (Perjeta™, Genentech)8. The combination of trastuzumab 
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with adjuvant chemotherapy is the current standard of treatment for HER2-positive patient population as it 
markedly improved outcomes among patients with HER2-positive early BC, reducing the risk of disease relapse 
and death9–12.
HER2 is a 185 kDa protein composed of three domains: a cytoplasmic domain with catalytic activity, a single 
transmembrane domain, and an extracellular (ECD) ligand-binding domain containing 647 amino acids. ECD is 
composed of four subdomains (I, II, III and IV) arranged as a tandem repeat of a two-subdomain unit, which can 
be cleaved from the surface of breast cancer cells by specific matrix metalloproteases13–15.
HER2 status of patients with BC and their eligibility for trastuzumab therapy have been determined using 
tissue-based tests such as immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH)16. However, 
these histological techniques requiring invasive biopsies are indicated to assess HER2 status in the primary 
tumor but cannot be used in the follow-up to monitor the disease and the response to treatment17,18. In this 
context, the detection of circulating HER2 ECD levels was proposed as a surrogate marker in metastatic BC 
(MBC) for a less invasive analysis of HER2 status in tissue18. In fact, serum HER2 ECD is currently suggested in 
the follow-up and monitoring of patients with MBC, whose initial serum HER2 value is above 15 ng mL−1 19, as 
high serum HER2 levels in MBC patients correlate with poor prognosis and decreased response to both conven-
tional (hormone-therapy and taxane) and anti-HER2 targeted (i.e. pertuzumab, trastuzumab) anticancer thera-
pies. However, available methods are not sufficiently sensitive for HER2 ECD determination in primary BC and 
during the treatment follow-up to identify acquired resistance to HER2-targeted antibody therapy. Moreover, it 
is impossible to compare results among studies evaluating the predictive role of HER2 ECD due to the lack of 
standardisation among the different immunoassays used (different cut-offs, different monoclonal antibodies with 
non-defined specificities).
In the present study we describe the development of sensitive enzyme-linked immunosorbent assays (ELISA), 
based on two epitope-specific monoclonal antibodies, namely MGR2 and MGR3, which were capable of correctly 
quantifying HER2 ECD also in presence of trastuzumab. The latter antibodies were developed in house and 
selected with the aim of further implementing applications in the clinical practice. Considering that trastuzumab 
can bind soluble HER2 ECD, its quantification through antibodies that (i) are fully characterized and (ii) rec-
ognise non-overlapping epitopes is crucial. Two sandwich ELISAs based on MGR2 and MGR3 epitope-specific 
mAbs for HER2 ECD were developed and validated. These mAbs were obtained through Balb/c mice immuniza-
tion with HER2 overexpressing Calu3 cells (lung adenocarcinoma)20 and were reported to recognize HER2 ECD 
epitope I and epitope III, respectively20,21, while trastuzumab recognises epitope IV14,22.
Moreover, a complete characterisation of mAb-HER2 ECD interaction was performed by means of surface 
plasmon resonance (SPR): non-overlapping epitope was confirmed between MGR2 and MGR3 and between both 
antibodies and trastuzumab. Association and dissociation constants were calculated and trastuzumab was used as 
control mAb for both epitope mapping and kinetics analysis.
Results
HER2 ECD/mAbs epitope binding pattern evaluation. In this study, the binding pattern of anti-HER2 
ECD mAbs was evaluated through a pair-wise binding approach, in which the ability of pairs of antibodies to bind 
simultaneously to the immobilised antigen was tested. The ability of multiple receptors to bind independently or 
to compete with each other for binding sites on a macromolecule can be easily tested by means of SPR, employing 
the Biacore technology23–25. With this technique, unlike conventional EIA (enzyme immunoassay) or RIA (radio 
immunoassay), there is no need for labelling of the reactants, and purification (cell supernatants can be used). 
Moreover, small amounts of reactants are sufficient for the epitope mapping23.
Concerning antibodies, those that are directed towards distinct epitopes will be able to bind simultaneously, 
while those that are directed towards the same epitopes will inevitably compete.
The monoclonal antibodies MGR2 and MGR3 were previously characterised and proved to recognise HER2 
ECD epitope I and epitope III20,21, respectively, whereas trastuzumab recognises epitope IV14,22.
HER2 ECD was covalently bound to the Biacore CM5 chip, and pairs of mAbs were sequentially injected 
following the pattern summarised in Table 1 and shown in Fig. 1, where the corresponding signals, expressed in 
response units (RUs), were recorded as sensograms after each injection.
It can be observed that the three mAbs do not compete for HER2 ECD binding. In fact, an increase of RU is 
observed when injecting the second mAbs (second injection) once the first one has reached saturation (first injec-
tion), thus confirming that epitopes recognised by MGR2, MGR3, and trastuzumab do not overlap. Comparable 
RU values were obtained switching mAbs in first and second injection, confirming that the binding of the first 
mAb does not interfere with the binding of the second one, independently from injection order. As for exam-
ple, RU = 821 with MGR2 only, and an additional RU = 1,027 was gained when trastuzumab is added (Fig. 1d). 
When the injection order is reverted, a starting RU = 1,062 was reached with trastuzumab only, and an additional 
RU = 801 was gained when MGR2 was injected (Fig. 1c).
First Injection (RU)
Second Injection (RU)
+ MGR2 + MGR3 + trastuzumab
MGR2 815 + 13 815 + 558 821 + 1,027
MGR3 636 + 704 643 + 41 639 + 965
trastuzumab 1,062 + 801 1,060 + 627 1,069 + 15
Table 1. Anti HER2 ECD mAbs epitope binding pattern evaluation.
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mAbs - HER2 ECD SPR kinetics experiments. Several data are available in literature concerning the 
affinity constant (KD) determination for trastuzumab-HER2 ECD interaction using Biacore instruments. In gen-
eral, all data refer to concentration ranging from sub-nanomolar to nanomolar.
In particular, KD of 0.4 nM (ka = 4.9 × 105 M−1 s−1; kd = 1.7 × 10−4 s−1)26, 1.9 nM (ka = 1.9 × 106 M−1 s−1; 
kd = 3.4 × 10−3 s−1)27, 0.10 nM (ka = 0.34 × 106 M−1s−1; kd = 0.42 × 10−4 s−1)28, 0.49 nM (ka = 8.46 × 104 M−1 s−1; 
kd = 4.15 × 10−5 s−1)29, and 9.4 nM (ka = 7.25 × 103 M−1 s−1; kd = 6.5 × 10−5 s−1)30 are reported, where KD = kd/ka, 
while ka and kd are the kinetic constants for the association and dissociation events, respectively.
Concerning trastuzumab, the results obtained in this work were comparable with those reported in litera-
ture and mentioned above, which indicated a KD in the sub-nanomolar range. Although some information were 
Figure 1. Competitive binding test for mAbs MGR2, MGR3, and trastuzumab toward immobilized HER2 
ECD, determined by Biacore X100. (a) Trastuzumab (1st injection) vs MGR3 (2nd injection); (b) MGR3 (1st 
injection) vs trastuzumab (2nd injection); (c) trastuzumab (1st injection) vs MGR2 (2nd injection); (d) MGR2 
(1st injection) vs trastuzumab (2nd injection); (e) MGR3 (1st injection) vs MGR2 (2nd injection) (f) MGR2 (1st 
injection) vs MGR3 (2nd injection).
4Scientific RepoRtS |         (2020) 10:3016  | https://doi.org/10.1038/s41598-020-59630-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
reported concerning MGR2 vs MGR3 in vitro effect20, their KD was only recently published and showed quite 
relevant standard deviation values. On the other hand, no data were available concerning ka and kd31.
In this work, we evaluated the binding properties of MGR2, MGR3 and trastuzumab toward HER2 ECD upon 
immobilisation of HER2 ECD onto CM5 chip.
Experiments were performed with mAbs diluted at the desired concentrations and injected over the function-
alised CM5 chip surface (0.25–30 nM for trastuzumab, 1–75 nM for MGR2, 2.5–200 nM for MGR3).
Kinetics data showed KD values of 0.19 nM (ka = 6.09 × 105 M−1 s−1; kd = 1.15 × 10−4 s−1) for trastuzumab, 
0.13 nM (ka = 2.04 × 105 M−1 s−1; kd = 2.73 × 10−5 s−1) for MGR2 and 3.56 nM (ka = 1.22 × 105 M−1 s−1; 
kd = 4.34 × 10−4 s−1) for MGR3.
It is worth noting that KD value for MGR2 showed the same order of magnitude than that for trastuzumab, 
while the KD value for MGR3 is at least one order of magnitude higher, mainly due to a higher kd. This finding can 
be easily visualised in the sensograms shown in Fig. 2, where it is possible to appreciate a difference between the 
dissociation phase of MGR3 (Fig. 2c, estimated kd = 4.34 × 10−4 s−1) when compared to the dissociation phase of 
trastuzumab (Fig. 2a, estimated kd = 1.15 × 10−4 s−1) and of MGR2 (Fig. 2b, estimated kd = 2.73 × 10−5 s−1). With 
respect to the KD, one order of magnitude difference between MGR2 and MGR3 was also previously reported31.
A comparison of the kinetic data for MGR2 and MGR3 shows that the former mAb has higher affinity for 
HER2 ECD in terms of both association and dissociation. However, the SPR data demonstrate the suitability of 
both the selected mAbs (MGR2 and MGR3) to be tested as capture antibodies for ELISA, as it will be discussed 
in the following paragraphs.
Development of sandwich ELISA procedure with mock samples. A sandwich ELISA protocol was 
optimised step-by-step by employing mock samples prepared by spiking the buffer with different concentra-
tions of recombinant HER2 ECD protein as the antigen, MGR2 or MGR3 as the capture antibodies, and a rabbit 
anti-human polyclonal antibody as the detection antibody. Serial dilutions of capture and detection antibodies 
were used to determine the working concentration for each reagent. The selected concentrations were 2 µg mL−1 
and 5 µg mL−1 for the capture antibodies MGR2 and MGR3, respectively, and 0.7 µg mL−1 for the detection 
antibody.
Optimization of blocking agent and time. The blocking step in ELISA is a key factor to reduce non-specific 
binding32, which can result in a high background signal, and poor sensitivity and specificity. Two commonly used 
protein blockers33 were selected and evaluated as blocking agents to reduce non-specific binding to unoccupied 
sites on the surface of ELISA plates: bovine serum albumin (BSA) and human serum albumin (HSA). HSA was 
preferred over BSA as it provided lower backgrounds and higher recovery performances. Thus, 2% HSA in PBS 
was used in all subsequent experiments as the blocking buffer. Samples and detection antibodies were prepared 
in a buffer containing a lower HSA concentration (1%) plus 0.1% Tween-20 in order to further reduce the back-
ground and minimize non-specific hydrophobic interactions34.
ELISA analytical validation. The sandwich ELISA was developed to detect HER2 ECD protein using MGR2 or 
MGR3 and a rabbit anti-HER2 ECD polyclonal antibody as capture and detection antibodies, respectively. We 
addressed several typical steps and optimised the parameters required for validation analysis to evaluate actual 
feasibility and possible challenges. Calibration curves for HER2 ECD recombinant protein were obtained in the 
concentration range from 0.19 to 12.50 ng mL−1 with both MGR2 and MGR3 as capture antibodies. Both assays 
provided a good linearity of the dose-response signal (Fig. 3) with correlation coefficients greater than 0.99.
Coefficients of intra- and inter-assay variation were assessed among replicates of at least twelve assays per-
formed in different days under the same operating conditions35, and resulted lower than 10% and 15%, respec-
tively (Supplementary Table S1), thus suggesting good assay precision. The lower limit of detection (LOD) and the 
lower limit of quantification (LOQ) were calculated as the concentrations corresponding to the mean absorbance 
of the zero plus three or ten times its standard deviation, respectively35. LODs were determined to be 0.76 ng mL−1 
for MGR2 and 0.75 ng mL−1 for MGR3. Similarly, the LOQs were 2.77 ng mL−1 and 2.85 ng mL−1 for MGR2 and 
MGR3, respectively (Supplementary Table S1).
Figure 2. SPR sensograms showing the kinetic analysis performed on HER2 ECD antigen immobilized on 
CM5 chip. mAbs were tested at the following concentrations: (a) 0.25–30 nM for trastuzumab; (b) 1–75 nM for 
MGR2; (c) 2.5–200 nM for MGR3. Association time 500 s, dissociation time 400 s.
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Quantification of HER2 ECD was performed by analysing two-fold serial dilutions of recombinant protein 
in assay buffer. The observed protein concentrations were in agreement with the expected values with a devia-
tion of ±20%, thus indicating assay linearity. The theoretical concentration was used to calculate percentage of 
recovery, which proved the assay reliability, as for it was included in the ranges of 85.4–115% (mean 102.2%) and 
91.2–106.6% (mean 98%) for MGR2 and MGR3-based assays, respectively.
ELISA mAb – pAb optimization and developing of dual mAbs-based sandwich ELISA. To improve signal ampli-
fication, the ELISA protocol was optimized using the biotin-streptavidin conjugation strategy. In fact, the 
use of the high-affinity and non-covalent interaction between biotin and streptavidin produced a maximized 
signal-to-noise with increased sensitivity compared to conventional enzyme-labeled secondary antibody36. 
Considering the high affinity shown in SPR experiments, MGR2 was selected as capture antibody and a goat 
anti-HER2 ECD biotinylated polyclonal as detection antibody. The calibration curve showed a linear behaviour 
in the range of 0.19–12.50 ng mL−1 with a correlation coefficient of 0.998.
Since MGR2 and MGR3 recognize two non-overlapping epitopes in HER2 ECD, a sandwich ELISA based 
on these two mAbs was also developed. To exploit the biotin-streptavidin conjugation strategy, the biotinyla-
tion of MGR2 and MGR3 was performed using the EZ-Link™Sulfo-NHS-LC Biotinylation Kit (code 21435, 
Thermo Fisher Scientific) following manufacturer’s instructions. MGR2 and MGR3 (1 mg mL−1) were labelled 
with 6.60 and 5.45 molecules of biotin, respectively. Assay set-up using MGR3 as capture antibody (5 µg mL−1) 
and biotinylated MGR2 as detection (15 µg mL−1) was identified as the best configuration in terms of curve range 
(0.19–12.50 ng mL−1) and coefficient of determination R2 (0.998) (Fig. 4).
Although the use of the dual mAb sandwich ELISA allowed also an acceptable detection in assay buffer, the 
pAb-based strategy was herein preferred for detection of native HER2 ECD in serum samples. In fact, native 
proteins in biological matrices like serum are more complex and their conformation could be altered by several 
factors affecting the strength of mAb-antigen interaction, including post-translational changes, temperature, pH 
range and salt concentration. These aspects are of minor concern when employing pAbs, which are more stable 
to pH and salt concentration variations. Moreover, the ability of pAbs to bind multiple epitopes allows signal 
amplification in sample with low level of expression of the target protein37.
Figure 3. ELISA standard curve for HER2 ECD quantification in the range 0–12.5 ng mL−1, employing (a) 
2 µg mL−1 MGR2 or (b) 5 µg mL−1 MGR3 mAbs as the capture antibodies and anti-HER2 ECD pAb as detection 
antibody. Error bars indicate standard deviation (SD).
Figure 4. ELISA standard curve for HER2 ECD quantification in the range 0.19–12.5 ng mL−1, employing 
5 µg mL−1 MGR3 as the capture antibody and 15 µg mL−1 biotinylated MGR2 as detector mAb. Error bars 
indicate SD.
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ELISA application to HER2 ECD spiked serum samples. Assay performance when quantifying HER2 ECD spiked 
in serum samples was evaluated in 11 serum matrix using samples from healthy donors available in the biobank 
of the Regional Centre Biomarkers and already tested as negative for soluble HER2 ECD (ADVIA Centaur HER2/
neu assay – Ref n° 00915031, Siemens Healthcare Diagnostics)38.
The potential effect of interferences arising from serum matrix was overcome by performing a 10-fold dilution 
of serum in the experimental buffer and by choosing HSA as blocking agent, which led to reduced backgrounds 
and higher recovery performances. In this setting, the analysis of HER2 ECD negative sera provided absorbance 
values comparable to the signal obtained with the experimental buffer alone, thus revealing an absence of matrix 
interference with respect to the quantification of HER2 ECD biomarker and reflecting the specificity of the test.
Assays performances for quantification of fixed amounts of recombinant HER2 ECD spiked in human serum, 
diluted 1:10 in the experimental buffer, was compared to the quantification of similar amounts of protein in 
experimental buffer. Assay accuracy and specificity were confirmed under these conditions, resulting in proper 
analytes quantification even in presence of potentially interfering serum components.
In particular, MGR2 provided a percentage of recovery of 100.8% (range 94–119.9%) in human serum spiked 
with HER2 ECD, while MGR3 performed slightly worse in human serum with a recovery of 76.8% (range 65.3–
92.7%). This evidence agreed well with the kinetic data acquired with the Biacore for MGR2 and MGR3, which 
showed that the former mAb has higher affinity for HER2 ECD in terms of both association and dissociation 
constants.
On these grounds, the assay relying on MGR2 and biotinylated pAb as capture and detection antibodies was 
selected for the validation of HER2 ECD measurements in clinical samples.
ELISA validation for HER2 ECD measurements in clinical samples. The validation process included the determi-
nation of precision, LOD, linearity, method comparison and bias estimation using patient samples. For all tests, 
samples were previously diluted 1:10 in assay buffer and tested in duplicate.
The assay was evaluated using serum samples of patients with histological diagnosis of stage II/III pri-
mary breast cancer (BC) collected between 1998 and 2001 and available in the biobank of the Regional Centre 
Biomarkers.
Coefficients of intra- and inter-assay variation were assessed as previously described and resulted lower than 
11 and 15%, respectively, suggesting an acceptable assay precision for the HER2 ECD measurement in clinical 
samples. LOD and LOQ were 0.76 ng mL−1 and 2.77 ng mL−1, respectively. Both assays showed high sensitivity, 
proving their suitability to detect HER2 ECD when present at low concentration in clinical samples.
The linearity of quantitative measurement procedure of HER2 ECD in clinical samples was determined 
accordingly to the EP06-A guideline39. Two HER2 ECD positive serum samples were selected from the biobank: 
the first one, containing 6.1 ng mL−1 of HER2 ECD, namely ‘serum low’ (SL), while the second one containing 
8.7 ng mL−1, namely ‘serum high’ (SH). Five samples were prepared with different SL:SH ratios: 1:0 (sample 1); 3:1 
(sample 2); 1:1 (sample 3); 1:3 (sample 4); and 0:1 (sample 5). Results are reported in Table 2 and Supplementary 
Fig. S1 shows the linearity of the measures.
Moreover, a comparison with two established commercial tests, used as reference, was conducted employing 
22 serum samples for the agreement analysis (11 for each method). The serum HER2 ECD levels previously 
tested with commercial methods (ADVIA Centaur HER2/neu assay, Siemens Healthcare Diagnostics – Ref n° 
00915031 and Quantikine Human ErbB2/HER2 Immunoassay, No. DHER20, R&D Systems) ranged from 3.6 to 
26.7 ng mL−1 (Supplementary Table S2).
Bland-Altman plots and Passing-Bablok regression analyses were used to assess agreement between the meth-
ods using MedCalc (v 14.10.2). The 95% upper and lower confidence intervals (CI) were estimated at −6.5 and 
6.4 when the developed assay was compared with ADVIA Centaur. The mean difference in the plot, due to the 
bias, was equal to zero, thus indicating that HER2 ECD measurements with the in-house developed ELISA are in 
agreement with those obtained with ADVIA Centaur (Fig. 5a). Similarly, the agreement analysis between in-house 
ELISA and the commercial ELISA kit Quantikine HER2 (Fig. 5b) showed a distribution of HER2 ECD values 
within the limits of agreement (95% CI, −4.4 and 4.8). In this case, the bias was close to zero (mean difference 
of 0.2). Moreover, in both comparative analyses using Passing-Bablok regression (Fig. 5c,d), the 95% CI for the 
intercept included the value 0, while the 95% CI for the slope included the value 1. Therefore, it can be stated that 
the developed assay and the two reference methods are in very good agreement, with an average bias in the range 
from 0 to +0.2 as shown before (Fig. 5a,b).
It is worth to emphasize that agreement analysis provided also information about the ex-vivo stability of HER2 
over time. In fact, the agreement between HER2 ECD levels assessed with the developed assay and those analysed 
Sample
SL:SH 
ratio
Expected HER2 ECD 
level (ng mL−1)
Observed HER2 
ECD level (ng mL−1) % Recovery
1 1:0 6.1 6.06 99.5
2 3:1 6.8 6.2 91.3
3 1:1 7.3 6.7 91.6
4 1:3 8 7.9 98.3
5 0:1 8.7 8.6 99.9
Table 2. Linearity of quantitative measurement procedure represented as percentage recovery (Expected/
Observed HER2 ECD level) for different proportions SL (Serum Low) and SH (Serum High).
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with ADVIA Centaur in samples collected between 1998 and 2001 demonstrated that HER2 ECD levels in sam-
ples stored in a bank for about 20 years at −80 °C are comparable with those measured in fresh samples. These 
results agree very well with previous reports describing no significant changes in the HER2 ECD levels after 
sample collection and storage at room temperature as well as after refrigeration at 2–8 °C or freezing at −20 or 
−80 °C40–42.
Evaluation of trastuzumab interference. As previously confirmed by SPR experiments, epitopes that are recog-
nized by MGR2, MGR3 and trastuzumab do not overlap.
The competitive binding of MGR2, MGR3, and trastuzumab towards HER2 ECD was also investigated by 
displacement tests. Before starting the experiment, HER2 ECD solutions were pre-incubated with two concen-
trations of trastuzumab (50 and 200 µg mL−1), which are included in the range of concentration within the mean 
minimum and the mean maximum measured in serum of patients, corresponding to 66 and 110 mg L−1, respec-
tively40. The solutions were then assayed with the MGR2 or MGR3-based assays and compared with freshly pre-
pared HER2 ECD solutions.
Noteworthy, the interference was limited and independent from the concentration of trastuzumab, thus sug-
gesting a possible steric hindrance instead of a competition for HER2 ECD binding. Trastuzumab interference 
was higher when HER2 ECD was at very low concentrations (3.13–1.56 ng mL−1), close to the LOQ of the ELISAs 
(2.77 or 2.85 ng mL−1 of HER2 ECD). Pre-incubation with 50 µg mL−1 of trastuzumab led the investigated HER2 
ECD concentration of 12.5 ng mL−1 to decrease of 7.9% or 23.9% with the MGR2- or MGR3-based assay, respec-
tively (Fig. 6a,b).
We hypothesize that this phenomenon might be due to the stoichiometric excess of the drug towards HER2 
ECD binding-site during the pre-incubation phase. It could be also observed that MGR3 was affected by 
Figure 5. Bland-Altman plot of differences between (a) ADVIA Centaur or (b) Quantikine HER2 ELISA 
kit and in house developed ELISA. Passing-Bablok regression analysis (n = 11 serum samples) comparing 
(c) ADVIA Centaur or (d) Quantikine HER2 ELISA kit with the in-house ELISA. In Bland-Altman analysis 
(panels a and b), the difference between the tested methods is plotted against the mean for HER2 ECD level. 
Black dotted lines show limits of agreement (95% CI) and the blue line shows the mean value of the differences 
between the two methods under comparison (the bias). The red dotted line is the zero line for assessing the 
discrepancy of the observed mean difference from zero. In Passing–Bablok agreement analyses (panels c and d), 
the data obtained with the in-house ELISA (y axis) is plotted against those of the commercial reference methods 
(x axis) together with the identity line (y = x) and the regression line. The regression line is continuous and blue, 
the red dotted line is the identity line (y = x) and the black dashed lines are the CI. Results are summarised as 
it follows. (c) regression equation, y = 1.41 + 0.87x; intercept, 1.41 (95% CI −5.85 to 7.39); slope, 0.87 (95% CI 
0.33 to 1.56). (d) regression equation, y = −0.37 + 1.08x; intercept, −0.37 (95% CI −3.17 to 2.86); slope, 1.08 
(95% CI 0.72 to 1.40).
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trastuzumab to a higher extent, when compared to MGR2, probably because of its lower affinity for HER2 ECD, 
as witnessed by SPR experiments.
Trying to overcome the hypothetical steric hindrance due to the binding of pAb to more than one epitope, 
and to balance the stoichiometry between the antibodies used, we performed a displacement test using the dual 
mAbs sandwich ELISA, with the configuration described previously. The experimental set up for trastuzumab 
displacement was maintained, testing 50 and 200 µg mL−1 of drug. Pre-incubation with 50 and 200 µg mL−1 of 
trastuzumab lowered the detection limit of 12.5 ng mL−1 of HER2 ECD of 19.5 and 22.5%, respectively. However, 
the interference decreased at lower concentrations of HER2 ECD (0.78 and 1.56 ng mL−1) with percentages rang-
ing from 4.66 to 15.5% while, at 0.39 ng mL−1 near the LOD (0.10 ng mL−1) and LOQ (0.30 ng mL−1) the interfer-
ence is absent (Fig. 6c).
To evaluate the presence of a significant difference between the linear regression curves of samples 
pre-incubated with trastuzumab and the standard curve, the analysis of covariance (ANCOVA) was performed. 
Neither the values of every slope, nor the related intercepts differed significantly from the standard solutions, 
indicating that the presence of trastuzumab in both the tested concentrations did not affect significantly the meas-
ured levels of HER2 ECD. Moreover, adjusting the concentration of the detection antibody allowed a reduction of 
the interference at lower HER2 ECD concentration with an optimization between the stoichiometric ratio of the 
antibodies involved in the detection.
Discussion
This study describes the development of a sandwich ELISA based on epitope specific monoclonal antibodies for 
HER2 ECD quantification. As previously described, monoclonal antibodies MGR2 and MGR3 recognise HER2 
ECD epitope I and epitope III, respectively20,21. Moreover, they do not compete for the same binding site of tras-
tuzumab, thus allowing to quantify soluble HER2 ECD, even when linked to trastuzumab.
The characterisation of epitope specificity patterns with a panel of mAbs gives valuable information to employ 
mAb in clinical, diagnostic, and technical contexts23. In this respect, the use of MGR2 or MGR3, as appropriately 
selected capture mAbs that recognise specific and characterized epitopes, would have the potential to allow cor-
relations of HER2 ECD with its clinical role qualitatively, as well as quantitatively.
Cancer investigators currently face challenges with respect to mAbs. In fact, the majority of antibodies are 
poorly characterized and not adequately validated for the variety of applications of interest to the research com-
munity41. As discussed by Haab et al.42, the user is forced to orient her/himself in an increasingly complex and 
intricate marketplace to determine whether data are available concerning the binding characteristics of an anti-
body and whether the antibody is suitable for a specific application.
Smaller in-house production operations can offer better characterizations of the antibodies than those offered 
by big companies43. In this context, although antibody-based assays exist, which employ antibodies that bind to 
different epitopes and that do not compete with trastuzumab44, the antibodies used in commercial ELISA kits 
do not recognise specifically mapped epitopes on HER2 ECD molecules. In this work, we exploited MGR2 and 
MGR3 mAbs that recognise and bind to specific epitopes of HER2 ECD to develop a sandwich ELISA. Our find-
ings showed, for the first time in this particular setting, lack of competition between MGR2 or MGR3 and trastu-
zumab, which specifically binds on the C-terminal portion of HER2 epitope IV. Presumably these mAbs do not 
compete also with the epitope II, which instead is recognized by pertuzumab45. Furthermore, our results demon-
strated the possibility to use both mAbs in the same assay as capture and detector, reaching good specificity and 
sensitivity also at low HER2 ECD levels and in presence of trastuzumab with no interference for quantifying 
the target protein. Moreover, the performance of this newly designed assay was compared against two validated 
commercial tests in quantifying HER2 ECD in serum samples and a good agreement among the three methods 
was observed in the majority of clinical samples, suggesting that the three methods are equally competent in 
identifying HER2 ECD, even at a low protein level.
Antibodies currently used in commercial ELISA kits do not recognise specifically mapped epitopes on the 
HER2 ECD protein. In this work, we investigated the properties of two highly characterized mAbs, MGR2 and 
MGR3, to develop and propose a reliable ELISA method to detect, quantify, and monitor HER2 ECD levels at 
concentrations that lay below the working range of commercial assays. Our findings also showed that such epitope 
Figure 6. Determination of HER2 ECD only (black dots) or pre-incubated with trastuzumab at 50 (red 
triangles) and 200 (blue squares) µg mL−1 employing (a) MGR2- or (b) MGR3-based assay and (c) the dual 
mAbs sandwich ELISA with MGR3 in coating and biotinylated MGR2 as the detection antibody. Error bars 
indicate SD but are too small to be visible.
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recognition is not interfering with the use of anticancer drug trastuzumab, thus making the developed ELISA 
assay a promising tool to monitor HER2 ECD levels also in patients under trastuzumab treatment. Moreover, the 
epitope-specificity of MGR2 and MGR3 antibodies increase their potential applicability in the development of 
new analytical tools that can be employed in the clinical practice. To conclude, we strongly believe that the present 
strategy shows promising applicability to be optimized in an assay for biomarkers quantification, as for example 
those describing the multiplexed electrochemical detection of protein biomarkers46 with the aim of establishing 
a point-of-care testing (PoCT) approach.
Methods
Chemicals. All the reagents and buffer components were purchased from Sigma-Aldrich, unless otherwise 
specified. Bi-distilled (dd-H2O) or Milli-Q grade water was used. Mouse monoclonal antibodies (IgG mAbs) 
MGR2 and MGR3 directed against the extracellular domain of HER2, obtained and purified as previously 
described20 were stored sterile at 4 °C in a buffer containing 150 mM sodium chloride and 0.02% sodium azide 
at pH 7.4.
Recombinant HER2 ECD protein (code 10004-HCCH, 70 kDa), and rabbit anti-human HER2 poly-
clonal antibody (IgG pAb, code 10004-RP04) were obtained from Sino Biological Inc. and stored in mul-
tiple aliquots at −20 °C. Goat anti human HER2 biotinylated polyclonal antibody (IgG pAb-biotin, code 
BAF1129) and Streptavidin-HRP conjugate (code DY998 Part #890803 5 vials) were from R&D Systems and 
stored at −20 °C and at 4 °C respectively. Goat anti-rabbit IgG-HRP conjugate (1 mg mL−1, code 401353) and 
3,3′,5,5′-Tetramethylbenzidine (TMB) liquid substrate system for ELISA (code ES001) were purchased from 
Merck Millipore and stored at 4 °C together with lyophilized human serum albumin (HSA, code A1653, 
Sigma-Aldrich).
Herceptin (trastuzumab 150 mg, Roche) was kindly provided by Dr. Renzo Lazzarini, Pharmaceutical 
Division, CRO Aviano, resuspended and stored as recommended by the manufacturer.
SPR sensor chip preparation and interaction assays. SPR measurements were performed with 
Biacore X100 instrument (GE), at 25 °C, with a flow rate of 30 µL min−1. CM5 sensor chips, running buffer 
(HBS-EP+) and Amine Coupling Kit (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), 
N-hydroxysuccinimide (NHS), 1.0 M ethanolamine-HCl pH 8.5) were purchased from GE.
The binding properties of MGR2, MGR3 and trastuzumab to HER2 ECD were evaluated upon immobilization 
of HER2 ECD onto CM5 chip surface in flow cell 2 (FC-2), using Biacore Amine Coupling Kit according to the 
manufacturer’s instructions. HER2 ECD was preliminary diluted to 10 µg mL−1 in acetate buffer (pH 4.5) and 
≈1,000 RU (Response Units) of HER2 ECD were immobilized onto the chip surface. Blank amine immobilization 
was performed on flow cell 1 (FC-1), used as reference.
Epitope overlapping/competition experiments and kinetics experiments were performed with mAbs diluted 
in HBS-EP + buffer 1X at the desired concentrations and injected over the functionalized surface. For kinetics 
experiments, 10 to 12 dilutions in the low nanomolar range were tested for each mAb.
Epitope overlapping/competition experiment were performed through a pair-wise binding approach by 
injecting one mAbs on HER2 EDC functionalised chip until binding sites saturation is reached (200 s), followed 
by a second injection (200 s) of the second mAb to evaluate competition.
Surface regeneration was performed with NaOH 10 mM for 30 s for both MGR2 and MGR3, and with NaOH 
50 mM for 20 s for trastuzumab. Surface regeneration conditions were evaluated and established after appropriate 
pH scouting experiments.
All sensograms were corrected by subtracting the signal recorded on FC-2 (functionalised cell) from the sig-
nal recorded of FC-1 (reference cell); collected data were evaluated by non-linear analysis of the association and 
dissociation curves using SPR kinetic evaluation software (BIAevaluation Software, version 2.0, Biacore). Data 
fitting was carried out with a 1:1 Langmuir binding model to obtain ka, kd and KD = kd/ka.
Fitting analysis was evaluated for all the performed assays and was compliant to the following statistical 
parameters: χ2 < 5% of Rmax, U-value < 25, SE (standard error) values < 5% of the corresponding parameters and 
tc > 108 (tc: flow rate independent part of the mass transfer constant).
ELISA procedure. 96-well microtiter plates (code 655001, Greiner Bio-One) were coated with mAb MGR2 
or MGR3 by incubating overnight at 4 °C with 100 µL/well of antibody at 2 µg mL−1 or 5 µg mL−1 in 10 mM of 
phosphate buffer pH 7.4 (PBS, code 524650, Merck Millipore), respectively. After removal of the coating solution, 
the coated plates were blocked with 300 µL/well of PBS containing 2% HSA for 1 h at 37 °C. Recombinant HER2 
protein was diluted at 12.5 ng mL−1 in PBS containing 1% HSA and 0.1% Tween 20 (experimental buffer) and 
used to generate a serial two-fold dilution standard curve. Standards and samples were dispensed onto the coated 
wells (100 µL/well), and plates were incubated at room temperature for 1 h. Rabbit pAb (0.7 µg/mL in experi-
mental buffer) was then added (100 µL/well) and plates were incubated at room temperature for 1 h. Horseradish 
peroxidase (HRP)-conjugated goat anti-rabbit IgG was then used as second labelled antibody (diluted 1:5,000 in 
experimental buffer, 100 µL/well). After further incubation for 30 min at room temperature, TMB substrate solu-
tion was added to develop the plates (100 µL/well) and the colour reaction was blocked after 10 min incubation 
at room temperature by addition of 0.18 M sulfuric acid (100 µL/well). Absorbance values at 450 nm and 655 nm 
were determined on a Biorad iMark microplate reader. When using the biotinylated pAb (0.2 µg mL−1 in exper-
imental buffer) or the biotinylated mAbs (15 µg mL−1 in experimental buffer) as detector antibody the following 
incubation was made using the Streptavidin-HRP conjugate (diluted 1:200 in experimental buffer, 100 µL/well). 
After each incubation step, plates were washed three times with PBS containing 0.1% Tween 20 (wash buffer) 
using an automated wash station (Bioplex Pro II) to remove unbound antigen and/or antibody. SigmaPlot 12.5 
software (Systat Software, Inc.) was used to determine the concentration of recombinant HER2 ECD protein 
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from absorbance values by using a recombinant HER2 ECD protein dissolved in experimental buffer at known 
concentrations as reference. Calibration curves were interpolated with a linear regression model. Linearity of the 
analytical procedure in the identified working range was evaluated by linear regression among data points.
Serum samples and ethical compliance. The overall study was conducted in accordance to the 
Declaration of Helsinki and its revisions and approved by the Local Ethical Committee (protocol 77190/2016, 
Ethics Committee for Clinical Experimentation of the Province of Venice and IRCSS San Camillo), which is 
organized and operates in accordance with Good Clinical Practice and the applicable laws and regulations. 
All tests were performed in accordance with relevant guidelines and regulations. A total of 33 serum samples 
obtained from the biobank of the Regional Centre for Biomarkers were tested in this study. HER2 ECD negative 
samples (n = 11), used to assess the precision and the linearity of the in-house ELISA, were obtained from healthy 
subjects who gave the informed consent for the use of samples for biomedical research in the field of tumor 
biomarkers at the time of donation to the biobank. HER2 ECD positive samples (n = 22), used to compare the 
newly designed assay with the two commercial tests, were obtained from patients with primary BC previously 
collected for diagnostic purposes, whose data were anonymized by coding. For these samples archived for more 
than twenty years, the need for informed consent was waived by the ethics committee in accordance with the 
requirements of Italian law (Italian Data Protection Authority - Garante Privacy, Authorisation no. 9/2014 – 
General Authorisation to Process Personal Data for Scientific Research Purposes. Published in Italy’s Official 
Journal No. 301 on 30th December 2014). After collection, all clinical samples were properly stored at −80 °C 
until quantification.
EZ-Link™Sulfo-NHS-LC biotinylation Kit. The biotinylation kit (code 21435, Thermo Fisher 
Scientific) includes desalting columns for purifying the labelled antibody and 4′-hydroxyazobenzene-2-
carboxylic acid (HABA) and avidin for measuring biotin incorporation. The biotinylation of MGR2 and MGR3 
was performed following manufacturer’s instructions using a 20-fold molar excess of NHS ester-activated biotin 
to label 1 mg mL−1 of mAbs to attach 4–6 biotin groups per molecule. Briefly, 1 mg mL−1 of MGR2 or MGR3 
was dissolved in 10 mM PBS provided. 6.8 µL of 10 mM Sulfo-NHS-LC Biotin, previously dissolved in ultrapure 
water, were added to both mAbs to react and incubated on ice for two hours. To remove the excess biotin reagent, 
the desalting columns were used after placing them into a 15 mL tube and centrifuging at 1000 g for 2 min. The 
columns were then equilibrated for three times by adding 2.5 mL of PBS to the top of the resin and centrifuging at 
1000 g for 2 min. The solution containing the biotinylated mAbs was spotted in the centre of the resin bed to allow 
the sample to absorb. A final centrifugation step was made to collect the purified labelled mAb. To estimate biotin 
incorporation, the HABA assay was performed by pipetting 180 µL of HABA/avidin solution into a micro well of 
a 96-well plate; the absorbance at 500 nm was measured and recorded as reference A500 nm HABA/Avidin; 20 µL of 
biotinylated mAb was added to the well and mixed; the absorbance at 500 nm was re-measured and biotin, thanks 
to its high affinity for biotin, displaces HABA interacting with avidin, and the absorbance at 500 nm decreases 
proportionately. According to the kit calculation procedures, 6.60 and 5.45 molecules of biotin were incorporated 
to MGR2 and MGR3, respectively.
Evaluation of serum HER2 ECD with ADVIA Centaur HER2 assay. HER2 ECD measurements in 
serum samples were performed as described before38 using this fully automated two-site sandwich immunoassay 
based on two specific anti-HER2 ECD mAbs (TA-1 and NB-3) and direct chemiluminescent technology, accord-
ingly to manufacturer ‘s instructions. Intra- and inter-assay CV% were less than 5%.
Evaluation serum HER2 ECD with Quantikine Human ErbB2/HER2 immunoassay. This com-
mercial kit (code DHER20, R&D Systems), which was used according to manufacturer ‘s instructions, is a quan-
titative sandwich ELISA assay based on an anti-HER2 mAb pre-coated onto a microplate. Intra- and inter-assay 
CV% were less than 4%.
Evaluation of trastuzumab interference. A solution was prepared diluting trastuzumab at 4 mg mL−1 in 
NaCl 9 g L−1 and stored in the dark at 4 °C. This solution was used as stock solution. Two concentrations of trastu-
zumab as interfering agent (50 or 200 µg mL−1) were added to the prepared HER2 test solutions, and the observed 
values were compared to those from standard HER2 calibration curve. In brief, before starting the experiment, 
the HER2 ECD test solutions were pre-incubated with 0 (only experimental buffer), 50 or 200 µg mL−1 of trastu-
zumab for 30 min at 4 °C to cover the concentration range 66–110 µg mL−1, found in serum samples by pharma-
cokinetics studies36. The three pre-incubated standard curves were then assayed and compared on the developed 
ELISA assays.
Data availability
The authors declare that all data supporting the findings of this study are available within the paper and its 
supplementary information files.
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